scholarly journals Concordance Study of CD30 Expression Detected By Multiple Immunohistochemistry Assays and Ventana CD30 Assay in Chinese Lymphoma Patients

Blood ◽  
2021 ◽  
Vol 138 (Supplement 1) ◽  
pp. 4553-4553
Author(s):  
Xiang-Nan Jiang ◽  
Yang Shi ◽  
Xiao-Qiu Li
Keyword(s):  
T Cell ◽  
B Cell ◽  
Malignant Lymphoma ◽  
Expert Panel ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large Cell ◽  
Ffpe Sample ◽  
T Cell Lymphoma ◽  
Chinese Patients

Abstract Background: CD30 is emerging as an important biomarker guiding the clinical diagnosis, treatment, and evaluating the efficacy and prognosis of lymphoma. However, there is no standard procedure for specification and interpretation of the pathological detection of CD30 in China. This study intends to evaluate the staining and interpretation concordance of CD30 expression detected by the VENTANA CD30 assay and other multiple immunohistochemistry (IHC) assay in Chinese malignant lymphoma patients. Design: This is a multi-center, observational study enrolling 1,000 adult patients with a diagnosis of histologically confirmed malignant lymphoma in China. Patients, aged 18 years or older at diagnosis and who provided available formalin-fixed paraffin-embedded (FFPE) samples stored within 2 years, with diagnosis of classical Hodgkin's lymphoma, anaplastic large-cell lymphoma, large cell transformation of mycosis fungoides, diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, extranodal NK/T-cell lymphoma, peripheral T cell lymphoma not otherwise specified, angioimmunoblastic T-cell lymphoma, and pcCD30+ T-cell lymphoproliferative disease were eligible to participate. Exclusion criteria included sample insufficiency for CD30 testing, incomplete sample information, lack of written informed consent. Methods: Each eligible patient provides an available r FFPE sample. Tissue slides obtained from each eligible FFPE sample will be stained by the VENTANA CD30 assay and at least one of the following IHC assays [umAB256 (zhongshanjinqiao) + Ventana BenchMark; Ber-H2 (Maixin) + Ventana BenchMark；Ber-H2 (Maixin) + DAKO; Ber-H2 (DAKO) + DAKO; Ber-H2 (DAKO) + Ventana BenchMark;umAB256 (Zhongshanjinqiao) + Leica; JCM182 (Leica) + Ventana BenchMark;JCM182 (Leica) + Leica; Ber-H2 (DAKO) + Leica]. CD30 expression of all immunostained slides will be independently interpreted as a percentage of CD30 positive cells by trained pathologists. The primary endpoint will be the staining concordance of percentages of positive cells for CD30 expression detected by each of the nine IHC assays and VENTANA CD30 assay (interpreted by expert panel) Secondary endpoints will be the interpretation concordance of pathologists at sites and the expert panel by assessing CD30 expression detected by various IHC assays. Both primary and secondary endpoint will be evaluated by intraclass correlation coefficient ICC, Bland-Altman, and Pearson correlation method. Discussion: This planned study will explore more equivalent testing methods to detect the expression of CD30 in Chinese patients with lymphoma. Disclosures Shi: Takeda Pharmaceuticals: Current Employment. Li: Takeda Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees, Other: Receiving lecture fees.

Response to brentuximab vedotin by CD30 expression: Results from five trials in PTCL, CTCL, and B-cell lymphomas.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 7543-7543
Author(s):  
Deepa Jagadeesh ◽  
Steven M. Horwitz ◽  
Nancy L. Bartlett ◽  
Ranjana H. Advani ◽  
Eric D. Jacobsen ◽  
...  
Keyword(s):  
T Cell ◽  
B Cell ◽  
Cell Lymphoma ◽  
Objective Response ◽  
B Cell Lymphoma ◽  
Large Cell ◽  
Brentuximab Vedotin ◽  
T Cell Lymphoma ◽  
Antibody Drug Conjugate ◽  
Non Hodgkin Lymphoma

7543 Background: Brentuximab vedotin (BV), an antibody-drug conjugate targeting CD30, has been evaluated in multiple trials in patients (pts) with peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL), or B-cell lymphoma. We examined the ability of CD30 expression level to predict response to BV across these patient populations. Methods: Data were integrated from 275 pts with PTCL, CTCL, and B-cell lymphoma treated with BV from 5 prospective clinical trials. Study SGN35-012 evaluated BV plus rituximab or BV monotherapy in pts with relapsed/refractory non-Hodgkin lymphoma. The ALCANZA study compared BV to physician’s choice of methotrexate or bexarotene in pts with mycosis fungoides (MF) or primary cutaneous anaplastic large cell lymphoma (pcALCL). Three investigator-sponsored trials evaluated BV monotherapy in pts with relapsed PTCL, MF, and pcALCL (35-IST-030, 35-IST-001, 35-IST-002). Exploratory analyses were conducted to examine the relationship between CD30 expression and objective response rate (ORR) for pts with CD30 expression ≥10%, <10%, or undetectable (0%) by IHC (malignant cells or lymphoid infiltrate; local review). Results: 143 pts had tumors with CD30 <10%, including 58/143 with undetectable CD30. Activity with BV was observed at all levels of CD30 expression, including CD30=0 (Table). Analysis of the interaction between CD30 and duration of response is ongoing and will be presented in the final poster. ORR by CD30 expression, n/N (%). Clinical trial information: NCT01421667, NCT02588651, NCT01578499, NCT01352520, NCT01396070. Conclusions: CD30 expression levels ≥10%, <10%, or undetectable did not predict response to BV in a range of CD30-expressing lymphomas: Clinical responses occurred in pts with CD30 low and CD30 undetectable lymphomas. Limitations of IHC, the dynamic nature and heterogeneity of cell-surface CD30 expression, and multiple mechanisms of action of BV may all contribute to this observation.[Table: see text]

Clinical Applications of the Genomic Landscape of Aggressive Non-Hodgkin Lymphoma

2017 ◽  
Vol 35 (9) ◽  
pp. 955-962 ◽  
Author(s):  
Andrea B. Moffitt ◽  
Sandeep S. Dave
Keyword(s):  
T Cell ◽  
B Cell ◽  
Hodgkin Lymphoma ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large Cell ◽  
T Cell Lymphoma ◽  
Adult T Cell Leukemia ◽  
Non Hodgkin Lymphoma ◽  
T Cell Lymphomas

In this review, we examine the genomic landscapes of lymphomas that arise from B, T, and natural killer cells. Lymphomas represent a striking spectrum of clinical behaviors. Although some lymphomas are curable with standard therapy, the majority of the affected patients succumb to their disease. Here, the genetic underpinnings of these heterogeneous entities are reviewed. We consider B-cell lymphomas, including Burkitt lymphoma, diffuse large B-cell lymphoma, Hodgkin lymphoma, and primary mediastinal B-cell lymphoma. We also examine T-cell lymphomas, including anaplastic large-cell lymphoma, angioimmunoblastic T-cell lymphoma, cutaneous T-cell lymphoma, adult T-cell leukemia/lymphoma, and other peripheral T-cell lymphomas. Together, these malignancies make up most lymphomas diagnosed around the world. Genomic technologies, including microarrays and next-generation sequencing, have enabled a better understanding of the molecular underpinnings of these cancers. We describe the broad genomics findings that characterize these lymphoma types and discuss new therapeutic opportunities that arise from these findings.

Clinicopathological Features of Malignant Lymphoma in JAPAN- Data From the Miyagi Study.

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 4997-4997
Author(s):  
Yukiko Miura ◽  
Joji Yamamoto ◽  
Katsura Kohata ◽  
Kenichi Ishizawa ◽  
Ryo Ichinohasama ◽  
...  
Keyword(s):  
T Cell ◽  
B Cell ◽  
Malignant Lymphoma ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Clinicopathological Features ◽  
T Cell Lymphoma ◽  
Newly Diagnosed ◽  
Malignant Lymphomas ◽  
Miyagi Prefecture

Abstract Abstract 4997 Background Malignant lymphoma comprises a diverse group of histologic categories. To date, several epidemiological studies in Japan have been reported, however, the data were collected from selected representative institutions, therefore, the results might not reflect the actual incidence and characteristics of malignant lymphoma in Japan. The Miyagi Study is a comprehensive epidemiologic study of malignant lymphoma, including immunologic and genetic information, constructed by a population-based registration system covering Miyagi prefecture, Japan. The population composition by age group and the population growth rate in Miyagi resembles national average figures, therefore, the clinicopathological features of in the Miyagi Study are likely representative of Japan. The purpose of this study was to determine the relative incidences and features of malignant lymphoma subtypes in Japan, compared to that of other countries. Methods A total of 1546 cases of malignant lymphoma newly diagnosed between 2002 and 2008 in Miyagi prefecture, of which the population is about 2.5 million, were enrolled in the Miyagi Study. Clinical and histopathological data including results of flow cytometry(FCM), immunohistochemistry (IHC), G-banding analysis with or without bicolor fluorescence in situ hybridization(FISH), southern blot analysis with or without polymerase chain reaction(PCR) were collected, and analysed. Results The median age of onset was 66 years and the male/female ratio was 1.13. Of the 1546 cases of newly diagnosed malignant lymphoma, 1160 cases (75%) were B-cell lymphomas, 287 cases (19%) were T-cell lymphomas, and only 81 cases (5%) were Hodgkin lymphomas. The most frequent subtype of B-cell lymphoma was diffuse large B-cell lymphoma (DLBCL), accounting for 52% of all B-cell lymphoma cases, followed by follicular lymphoma (FL) and extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), accounting for 24% and 8% of B-cell lymphoma cases, respectively. The most frequent subtypes of T/NK-cell lymphoma were peripheral T-cell lymphoma, unspecified (PTCLU), angioimmunoblastic T-cell lymphoma(AILT) and adult T-cell lymphoma, accounting for 30%, 15% and 14% of cases, respectively. The relative frequency of malignant lymphoma subtypes was similar to that of Japan reported in 2000 by Lymphoma Study Group of Japanese Pathologists, though there were some differences, such as the high incident rate of FL. There was not a notable time trend in the proportion of FL in B-NHL through 7 years, since it accounted for 20.3% in 2002 and 24.0% in 2008. Within the B-cell lymphoma group, there was a higher frequency of indolent B-cell lymphomas in women (39.8%) compared to men (29.8%). The rates of CD20 and CD22 positivity, as analysed by FCM, were 94.9% and 96.3% in DLBCL, 99.2% and 98.4% in FL, and 98.4% and 100% in MALT lymphoma, respectively. The t(14;18) translocation, a frequent chromosomal abnormality of FL, was present in 63.9% of FL patients, which is less frequent compared with the reports from western countries. De novo CD5+ DLBCL, which is known to have poor outcome, accounted for 21.6% of DLBCL, a frequency higher than previously reported. Conclusions The relative frequency of the subtypes of malignant lymphomas in Miyagi is distinct from that of Western countries and shares some similarities with other Asian countries. In the present study, FL was found to be the second largest subtype of malignant lymphoma, consistent with previous reports that FL is increasing in Far East Asia including Japan, Korea and Taiwan. The results of this study reveal the clinicopathologic characteristics of malignant lymphomas in Japan. Disclosures No relevant conflicts of interest to declare.

Tryptophan Catabolism Is Associated with Clinical Outcome of Patients with Malignant Lymphoma

Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 4146-4146
Author(s):  
Soranobu Ninomiya ◽  
Hisashi Tsurumi ◽  
Takeshi Hara ◽  
Masato Hoshi ◽  
Naoe Goto ◽  
...  
Keyword(s):  
T Cell ◽  
B Cell ◽  
Healthy Volunteers ◽  
Malignant Lymphoma ◽  
Poor Prognosis ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Local Immunity ◽  
Tryptophan Catabolism

Abstract Abstract 4146 Background: Indoleamine 2,3-dioxygenase (IDO) exerts powerful immunomodulatory effects through its enzymatic activity that leads to catabolism of the essential amino acid l-tryptophan. Some metabolites derived from tryptophan generated by IDO such as L-kynurenine, block Ag-driven specific T-cell proliferation and induce T-cell death. Therefore, IDO activity might play an important role in regulation of the immune response exerted by antigen presenting cells and also provide transformed cells with a potent tool to help escape from assault by the immune system. The activity of IDO can be estimated by measuring the serum concentration of l-tryptophan and l-kynurenine. We have previously described that high serum l-kynurenine level is associated with poor prognosis of diffuse large B-cell lymphoma (DLBCL) (Yoshikawa et al. Eur J Hemat 2009). Here, we investigated the tryptophan catabolism in malignant lymphoma. Patients and methods: The study protocol comprised a prospective, consecutive entry design that was approved by our Institutional Review Board. We investigated 163 patients between December 2002 and March 2010 who were histologically diagnosed with malignant lymphoma and 20 healthy adult volunteers. L-tryptophan and l-kynurenine were measured by high performance liquid chromatography. Patients with CD 20 positive NHL received 6 to 8 cycles of either R-CHOP therapy. Each regimen consisted of rituximab, cyclophosphamide, doxorubicin or tetrahydropyranyl-adriamycin, an anthracycline derivative of DOX, vincristine, and prednisolone. Patients with CD 20 negative NHL aged received 6 to 8 cycles of either CHOP therapy. Patients with Hodgkin lymphoma received ABVD therapy. Patients with bulky disease received radiotherapy ranging from 30 to 40 Gy. Some patients with refractory or relapsed NHL who responded to (R)-P-IMVP-16/CBDCA received high-dose chemotherapy followed by autologous stem cell transplantation. Results: The pathology of underlying comprised Hodgkin lymphoma (n=10), DLBCL (n=75), lymphoblastic lymphoma (LBL, n=3), Burkitt lymphoma (Burkit, n=2), follicular lymphoma (FL, n=28), mantle cell lymphoma (MCL, n=4), mucosa-associated lymphoid tissue lymphoma (MALT, n=14), small lymphocytic lymphoma (SLL, n=2), lymphoplasmacytic lymphoma (LPL, n=4), anaplastic large cell lymphoma (ALCL, n=4), peripheral T-cell lymphoma, unspecified (PTCL-U, n=13), and NK/T cell lymphoma (NK/T, n= 4). The median serum l-kynurenine levels in patients (2.29 ± 4.97 mM) were significantly higher than in healthy volunteers (1.13 ± 0.32 mM). The ratio of l-kynurenine/l-tryptophan levels in patients with ML (0.040 ± 0.487) was significantly higher than in healthy volunteers (0.022 ± 0.009). We found no significant correlations between l-kynurenine or l-tryptophan and lymphoma histology. Regardless of the pathologic classification, median l-kynurenine levels in lymphoma patients were higher than in healthy volunteers. We established the cut-off value of l-kynurenine at 2.2 mM which was essentially the median for all patients. In the aggressive B cell lymphoma patients (DLBCL, Burkit, and LBL, n=81), the 3-year OS rates with l-kynurenine < 2.2 mM and ≥ 2.2 mM were 69.5% and 43.6%, respectively (P <0.05). While, in the indolent B cell lymphoma patients (FL, MALT, MCL, LPL and SLL, n=51), the 3-year OS rates with l-kynurenine < 2.2 mM and ≥ 2.2 mM were 95% and 90.6%, respectively (N.S). In the T cell lymphoma patients (ALCL, PTCL, and NK/T n=21), the 3-year OS rates with l-kynurenine < 2.2 mM and ≥ 2.2 mM were 75% and 55.2%, respectively (N.S). Conclusion: Serum l-kynurenine was a significant predictor for the survival of aggressive B cell lymphoma patients. The increase in serum l-kynurenine levels is thought to be caused by enhanced l-tryptophan catabolism, which inhibits tumoral local immunity. The result of a poor prognosis among patients with high l-kynurenine levels indicates that depressed local immunity due to enhanced IDO activity contributes to becoming refractory to treatment. Disclosures: No relevant conflicts of interest to declare.

Histopathological features and immunophenotyping of canine transmural gastrointestinal lymphoma using full-thickness biopsy samples

2021 ◽  
pp. 030098582110305
Author(s):  
Kazuhiro Kojima ◽  
James K. Chambers ◽  
Tatsuhito Ii ◽  
Kazumi Nibe ◽  
Takuya Mizuno ◽  
...  
Keyword(s):  
T Cell ◽  
B Cell ◽  
Who Classification ◽  
Cell Lymphoma ◽  
Granzyme B ◽  
B Cell Lymphoma ◽  
Large Cell ◽  
T Cell Lymphoma ◽  
World Health ◽  
Gastrointestinal Lymphomas

To elucidate the histopathological characteristics and immunophenotypes of canine transmural “mass-forming” gastrointestinal lymphomas and plasmacytomas, 83 surgically resected biopsy samples were examined. All lymphomas and plasmacytomas were located in the small or large intestine except for 1 plasmacytoma which was in the stomach. According to the World Health Organization (WHO) classification, B-cell neoplasms (17 cases) included lymphoplasmacytic lymphoma (6/17), plasmacytoma (5/17), follicular lymphoma (3/17), and diffuse large B-cell lymphoma (3/17). Based on nuclear sizes, T-cell neoplasms (66 cases) were broadly divided into large cell lymphoma (LCL; 48/66) and small cell lymphoma (SCL; 18/66). According to the WHO classification, T-cell neoplasms included anaplastic large T-cell lymphoma (ALCL; 10/66), angiotropic T-cell lymphoma (3/66), mixed inflammatory type peripheral T-cell lymphoma (mixed inflammatory type PTCL; 33/66), and PTCL-not otherwise specified (PTCL-NOS; 20/66). Mixed inflammatory type PTCLs were further divided into histiocyte- (27/33) and eosinophil- (6/33) dominant types. Immunohistochemically, lymphoplasmacytic lymphomas were positive for Pax5 (6/6) and IgM (5/6), while plasmacytomas were positive for IgG (5/6) and negative for Pax5. LCLs were immunopositive for granzyme B in 31/48 cases (65%) and CD8 in 9/48 cases (19%), while SCLs were immunopositive for granzyme B in 3/18 cases (17%) and CD8 in 3/18 cases (17%). Furthermore, 8/10 cases (80%) of ALCL and 19/27 cases (70%) of histiocyte-dominant PTCL were immunopositive for granzyme B, whereas 6/20 cases (30%) of PTCL-NOS, 1/6 cases (17%) of eosinophil-dominant PTCL, and no cases of angiotropic T-cell lymphomas were immunopositive for granzyme B. The present study describes the immunophenotypes in different histological types of transmural gastrointestinal lymphomas in the dog.

scholarly journals Epidemiology of Non-Hodgkin’s Lymphoma

2021 ◽  
Vol 9 (1) ◽  
pp. 5
Author(s):  
Krishna C. Thandra ◽  
Adam Barsouk ◽  
Kalyan Saginala ◽  
Sandeep Anand Padala ◽  
Alexander Barsouk ◽  
...  
Keyword(s):  
T Cell ◽  
Radiation Treatment ◽  
Cell Lymphoma ◽  
Breast Implants ◽  
Occupational Exposures ◽  
B Cell Lymphoma ◽  
Large Cell ◽  
T Cell Lymphoma ◽  
Human Herpes Virus 8 ◽  
Human T Cell

Non-Hodgins’s lymphoma (NHL) is the most common hematological malignancy worldwide, accounting for nearly 3% of cancer diagnoses and deaths. NHL is the seventh most prevalent cancer and has the sixth highest mortality among cancers in the US. NHL accounts for 4% of US cancer diagnoses, and incidence has increased 168% since 1975 (while survival has improved 158%). NHL is more common among men, those >65 years old, and those with autoimmune disease or a family history of hematological malignancies. NHL is a heterogenous disease, with each subtype associated with different risk factors. Marginal zone lymphoma (MZL) is strongly associated with Sjogren’s syndrome (SS) and Hashimoto’s thyroiditis, while peripheral T-cell lymphoma (PTCL) is most associated with celiac disease. Occupational exposures among farm workers or painters increases the risk of most of the common subtypes. Prior radiation treatment, obesity, and smoking are most highly associated with diffuse large B-cell lymphoma (DLBCL), while breast implants have been rarely associated with anaplastic large cell lymphoma (ALCL). Infection with Epstein–Barr Virus (EBV) is strongly associated with endemic Burkitts lymphoma. HIV and human herpes virus 8 (HHV-8), is predisposed to several subtypes of DLBCL, and human T-cell lymphoma virus (HTLV-1) is a causative agent of T-cell lymphomas. Obesity and vitamin D deficiency worsen NHL survival. Atopic diseases and alcohol consumption seem to be protective against NHL.

Composite diffuse large B-cell lymphoma and CD20-positive peripheral T-cell lymphoma

2011 ◽  
Vol 61 (11) ◽  
pp. 662-666 ◽  
Author(s):  
Sho Yamazaki ◽  
Yosei Fujioka ◽  
Fumihiko Nakamura ◽  
Satoshi Ota ◽  
Aya Shinozaki ◽  
...  
Keyword(s):  
T Cell ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Peripheral T Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Primary T-Cell–Rich B-Cell Lymphoma Masquerading as a Meningioma

2000 ◽  
Vol 124 (11) ◽  
pp. 1700-1703
Author(s):  
Barbara H. Amaker ◽  
Nitya R. Ghatak ◽  
Sean A. Jebraili ◽  
Andrea Ferreira-Gonzalez ◽  
Michael J. Kornstein
Keyword(s):  
T Cell ◽  
B Cell ◽  
Cell Lymphoma ◽  
Prognostic Significance ◽  
B Cell Lymphoma ◽  
Large Cell ◽  
Molecular Techniques ◽  
First Case ◽  
Dural Lymphoma ◽  
Immunohistochemical Techniques

Abstract Primary dural lymphoma is rare, and few of the small number of cases reported to date have been classified using immunohistochemical techniques. To our knowledge, we report the first case of T-cell–rich B-cell lymphoma (diffuse mixed small cell and large cell) presenting as a solitary intracranial dural mass. Cytologic and frozen sections prepared during intraoperative consultation revealed a polymorphic population of lymphocytes suspicious for an inflammatory process. Permanent sections of the dura showed a diffusely infiltrating mass composed of mature lymphocytes peppered with large atypical lymphocytes. Immunohistochemical stains identified the small lymphocytes as T cells (CD3 and CD43) and the large atypical lymphocytes as B cells (CD20). Evidence of rearranged immunoglobulin heavy-chain genes demonstrated B-cell monoclonality. Differentiating between inflammatory and neoplastic lymphocytic masses of the dura obviously has important therapeutic and prognostic significance and may require immunohistochemical and molecular techniques.

Direct comparisons of peripheral T-cell lymphoma with diffuse B-cell lymphoma of comparable histological grades--should peripheral T-cell lymphoma be considered separately?

1989 ◽  
Vol 7 (6) ◽  
pp. 725-731 ◽  
Author(s):  
A L Cheng ◽  
Y C Chen ◽  
C H Wang ◽  
I J Su ◽  
H C Hsieh ◽  
...  
Keyword(s):  
T Cell ◽  
B Cell ◽  
Induction Chemotherapy ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
T Cell Lymphoma ◽  
High Grade ◽  
Peripheral T Cell Lymphoma ◽  
Laboratory Features ◽  
Hodgkin's Lymphomas

Peripheral T-cell lymphoma (PTCL) forms a morphologically heterogeneous group of non-Hodgkin's lymphomas (NHL) with distinct immunophenotypes of mature T cells. Progress has been slow in defining specific clinicopathological entities to this particular group of NHL. In order to elucidate the specific characteristics of PTCL, a direct comparison of PTCL with a group of diffuse B-cell lymphomas (DBCL) was performed. Between June 1983 and December 1987, we studied 114 adults with NHL, using a battery of immunophenotyping markers. Adult T-cell leukemia/lymphoma, lymphoblastic lymphoma, mycosis fungoides/Sézary syndrome, follicular lymphoma, well-differentiated lymphocytic lymphoma, and true histiocytic lymphoma were excluded from this study since these are distinct clinicopathologic entities with well-recognized immunophenotypes. Of the remaining 75 patients, 70 who had adequate clinical information were analyzed, and of these, 34 were PTCL and 36 were DBCL. Classified according to the National Cancer Institute (NCI) Working Formulation (WF), 68% of PTCL and 31% of DBCL were high-grade lymphomas. Clinical and laboratory features were similar, except PTCL had a characteristic skin involvement and tended to present in more advanced stages with more constitutional symptoms. Induction chemotherapy was homogeneous in both groups, and complete remission rates were 62% for PTCL and 67% for DBCL. Patients with DBCL had a better overall survival than patients with PTCL, but the survival benefit disappeared after patients were stratified according to intermediate- or high-grade lymphoma. A subgroup of PTCL patients who had received less intensive induction chemotherapy was found to have a very unfavorable outcome. We conclude that (1) PTCL follows the general grading concept proposed in WF classification; (2) within a given intermediate or high grade, PTCL and DBCL respond comparably to treatment; (3) the intensity of induction chemotherapy has a crucial impact on the outcome of PTCL patients; and (4) with a few exceptions, the clinical and laboratory features of PTCL and DBCL are comparable.

scholarly journals Composite Lymphoma Comprising Extranodal NK/T-Cell Lymphoma and Diffuse Large B-Cell Lymphoma

2018 ◽  
Vol 2018 ◽  
pp. 1-4
Author(s):  
Shin Nagai ◽  
Junji Hiraga ◽  
Noriyuki Suzuki ◽  
Naruko Suzuki ◽  
Yusuke Takagi ◽  
...  
Keyword(s):  
T Cell ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Composite Lymphoma ◽  
Large B Cell Lymphoma ◽  
Positron Emission ◽  
Nk T Cell ◽  
Large B Cell

We report a rare case of composite lymphoma comprising extranodal NK/T-cell lymphoma, nasal type, (ENKL) and diffuse large B-cell lymphoma (DLBCL) in a 70-year-old man complaining of fatigue. Computed tomography showed multiple consolidations in both lungs, and ENKL was diagnosed from transbronchial lung biopsy. Positron emission tomography also detected abnormal uptake in the stomach, and DLBCL was diagnosed from subsequent gastroscopy. Two courses of chemotherapy including rituximab achieved reduction in DLBCL, but ENKL proved resistant to this treatment and progressed. Concomitant ENKL and DLBCL have not been previously described among reports of composite lymphomas.

Sign in / Sign up

Export Citation Format

Share Document